Table 1 Clinical characteristics of study patients. (N = 938)
Total (N = 938) | IPF with lung cancer (n = 135) | IPF without lung cancer (n = 803) | P value | |
|---|---|---|---|---|
Age, years | 65.6 ± 8.1 | 65.2 ± 7.2 | 65.7 ± 8.2 | 0.479 |
Gender, male | 744 (79.3) | 128 (94.8) | 616 (76.7) | < 0.001 |
Smoking | ||||
Current | 220 (23.5) | 60 (44.4) | 160 (19.9) | < 0.001 |
Ex-smoker | 462 (49.3) | 74 (54.8) | 390 (48.6) | |
Never smoker | 256 (27.3) | 1 (0.8) | 253 (31.5) | |
FVC, % | 83.0 ± 18.6 | 89.5 ± 14.8 | 81.9 ± 19.0 | < 0.001 |
FVC < 80% | 316/818 (38.6) | 24/115 (20.9) | 292/703 (41.5) | < 0.001 |
DLco, % | 71.3 ± 20.9 | 73.2 ± 20.3 | 71.0 ± 21.0 | 0.290 |
DLco < 80% | 475/724 (65.6) | 67/105 (63.8) | 408/619 (65.9) | 0.675 |
FEV1/FVC < 70% | 101/795 (12.7) | 25/111 (22.5) | 76/684 (11.1) | 0.001 |
Decline of FVC ≥ 10%/yeara | 148/691 (21.4) | 18/92 (19.6) | 130/599 (21.7) | 0.642 |
Decline of DLco ≥15%/yeara | 132/571 (23.1) | 12/81 (14.8) | 120/490 (24.5) | 0.056 |
Use of azathioprineb | 96 (10.2) | 11 (8.1) | 85 (10.6) | 0.387 |
Use of steroidb | 123 (13.1) | 13 (9.6) | 110 (13.7) | 0.195 |
Follow-up duration, years | 4.5 ± 3.1 | 3.8 ± 2.6 | 4.6 ± 3.2 | 0.002 |